Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.69 |
| ▸ | BRD4 | O60885 | 3/20 | 0.69 |
| ▸ | BRD2 | P25440 | 3/20 | 0.69 |
| ▸ | BRD3 | Q15059 | 3/20 | 0.69 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | CSF1R | P07333 | 8/20 | 0.59 |
| ▸ | EGFR | P00533 | 2/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29484297 | 1.00 | CYP3A4 (0.69) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL2724277 | 0.85 | CSF1R (0.59) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL2723827 | 0.85 | CSF1R (0.64) | PDE4BCSF1REGFRERBB2 | |
| SCHEMBL2726281 | 0.84 | CYP3A4 (0.83) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL14756281 | 0.83 | CYP3A4 (0.75) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL2725837 | 0.82 | CSF1R (0.61) | PDE4BCSF1REGFRERBB2 | |
| SCHEMBL18904314 | 0.81 | CYP3A4 (0.70) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL13731747 | 0.80 | CYP3A4 (0.72) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL2725458 | 0.79 | CSF1R (0.59) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL2726408 | 0.79 | CSF1R (0.63) | PDE4BCSF1REGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635279-A2 | CHEMICAL COMPOUNDS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2013-09-11 | — | — | EP | claimed |
| US-20130225524-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2013-08-29 | — | — | US | claimed |
| WO-2012061557-A2 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-05-10 | — | — | WO | claimed |
| US-20250352519-A1 | TREATING PRIMARY OR IDIOPATHIC HYPEROXALURIA WITH SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE | UNIV VANDERBILT (US) | 2025-11-20 | — | — | US | disclosed |
| EP-3954685-B1 | SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF | US HEALTH (US) | 2025-08-27 | — | — | EP | disclosed |
| US-12365653-B2 | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2025-07-22 | — | — | US | disclosed |
| US-12233051-B2 | Treating primary or idiopathic hyperoxaluria with small molecule inhibitors of lactate dehydrogenase | VANDERBILT UNIVERSITY (US) | 2025-02-25 | — | — | US | disclosed |
| US-20240368087-A1 | SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2024-11-07 | — | — | US | disclosed |
| US-11897845-B2 | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-02-13 | — | — | US | disclosed |
| US-20240000949-A1 | Nucleic Acid-Derivatized Therapeutics | UNIV CHICAGO (US) | 2024-01-04 | — | — | US | disclosed |
| US-20230372308-A1 | TREATING PRIMARY OR IDIOPATHIC HYPEROXALURIA WITH SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE | VANDERBILT UNIVERSITY | 2023-11-23 | — | — | US | disclosed |
| US-10351532-B2 | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-07-16 | — | — | US | disclosed |
| EP-3478677-A1 | 1 H-PYRAZOL-1 -YL-THIAZOLES AS INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2019-05-08 | — | — | EP | disclosed |
| US-20180273488-A1 | SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF | THE UAB RESEARCH FOUNDATION | 2018-09-27 | — | — | US | disclosed |
| WO-2018005807-A1 | 1 H-PYRAZOL-1 -YL-THIAZOLES AS INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-01-04 | — | — | WO | disclosed |
| EP-3240785-A2 | SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016109559-A2 | SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-07-07 | — | — | WO | disclosed |
| EP-2635279-A2 | CHEMICAL COMPOUNDS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2013-09-11 | — | — | EP | disclosed |
| US-20130225524-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2013-08-29 | — | — | US | disclosed |
| WO-2012061557-A2 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372308-A1 | TREATING PRIMARY OR IDIOPATHIC HYPEROXALURIA WITH SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE | XDH, GLS, LDHA | CYP3A4 1394/4885CYP2C9 734/4885BRD4 4159/4885 |
| US-20250352519-A1 | TREATING PRIMARY OR IDIOPATHIC HYPEROXALURIA WITH SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE | XDH, GLS, LDHA | CYP3A4 1649/4885CYP2C9 751/4885BRD4 4252/4885 |
| US-20130225524-A1 | Chemical Compounds | LDHA, NQO2, LDHB | CYP3A4 163/4885CYP2C9 284/4885BRD4 1425/4885 |
| US-20180273488-A1 | SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF | LDHB, LDHA, PDHB | CYP3A4 2693/4885CYP2C9 2785/4885BRD4 3854/4885 |
| US-11897845-B2 | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof | LDHB, LDHA, PDHA1 | CYP3A4 2578/4885CYP2C9 2943/4885BRD4 3587/4885 |
| US-10351532-B2 | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof | LDHB, LDHA, PDHB | CYP3A4 2620/4885CYP2C9 2977/4885BRD4 3628/4885 |
| US-12365653-B2 | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof | LDHB, LDHA, PDHA1 | CYP3A4 2578/4885CYP2C9 2943/4885BRD4 3587/4885 |
| US-20240368087-A1 | SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF | LDHB, LDHA, PDHA1 | CYP3A4 2578/4885CYP2C9 2943/4885BRD4 3587/4885 |
| US-20240000949-A1 | Nucleic Acid-Derivatized Therapeutics | NSUN2, NSUN3, POLRMT | CYP3A4 4831/4885CYP2C9 4734/4885BRD4 1810/4885 |
| US-12233051-B2 | Treating primary or idiopathic hyperoxaluria with small molecule inhibitors of lactate dehydrogenase | XDH, GLS, LDHA | CYP3A4 1394/4885CYP2C9 734/4885BRD4 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.